Heart Failure: In-Hospital Initiation of Dapagliflozin in Acute Heart Failure (DAPA ACT HF-TIMI 68)

What is the Purpose of this Study?

The purpose of this study is to evaluate whether a drug called dapagliflozin is safe and effective when added to conventional heart failure therapy in patients who have been admitted to the hospital for acute heart failure. Participants will be randomly assigned to receive either dapagliflozin or placebo (inactive substance). In addition, they be asked about their medical history and medications, as well as their health and quality of life. Blood samples will also be taken to check creatinine and potassium levels. 

Dapagliflozin has been approved by the U.S. Food and Drug Administration (FDA) for various conditions, but its use in this study is investigational.


Eligibility

  • Age ≥18 years (male or female)
  • Currently hospitalized for AHF defined as meeting all the following criteria:
Show more

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68

Study Details
Disease Type/Condition

Heart failure

Principal Investigator

Cole, Robert

Age Group

Adult

Phase

III/IV

IRB Number

STUDY00001619

ClinicalTrials.gov ID

NCT04363697

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Heart failure

Principal Investigator

Cole, Robert

Age Group

Adult

Phase

III/IV

IRB Number

D1690C00078

ClinicalTrials.gov ID

NCT04363697

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org